India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug

India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India.